



Pathogenesis and Therapy of Neurovascular Compression Syndromes

Guest Editor:

Dr. Bartosz Szmyd

Department of Neurosurgery and
Neuro-Oncology, Medical
University of Lodz, Lodz, Poland

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear Colleagues,

Neurovascular compression syndromes are challenging disorders resulting from the compression of cranial nerves at the transition zone. Their exact pathomechanism remains unclear. The most likely chain of events leading to neurovascular compression symptoms is vascular compression in the transition zone → demyelination → nucleus hyperexcitability → symptoms. The proposed Special Issue aims to enhance efforts leading to better insights into the pathogenesis of neurovascular compression syndromes and its possible link to new therapeutic approaches. We encourage authors to submit papers related to the following aspects of pathogenesis/treatment:

- Anatomical and/or hemodynamical variability;
- Nerve structure alternations;
- Nucleus hyperexcitability;
- Brain white/gray matter changes;
- Disturbances in ion channels;
- Inflammatory background;
- Altered proteome and biochemical parameters;
- Other possible aspects of the pathogenesis of neurovascular compression syndromes;
- Therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI